US pharma giant Merck & Co (NYSE: MRK) has won out in a lawsuit relating to Bridion (sugammadex), a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium in general anesthesia.
The US District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly calculated the patent term extension period for the primary patent related to the drug.
This period is designed to restore some of the patent life lost during the regulatory review process for new drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze